ライフサイエンスコーパス: Janus kinase

1 plex stabilization related to the associated Janus kinases.

2 ciated signal transduction machinery such as Janus kinases.

3 ockade of IL-12 and IL-23; and inhibition of Janus kinases.

4 we discovered that miR-373 directly targets Janus kinase 1 (JAK1) and IFN-regulating factor 9 (IRF9)

5 f the FERM and SH2-like domains of the human Janus kinase 1 (JAK1) bound to a fragment of the intrace

6 enes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurre

7 mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides

8 eron (IFN) signaling antagonist by targeting Janus kinase 1 (JAK1).

9 main-containing protein (RLTPR); moesin; and Janus kinase 1 (JAK1).

10 In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity

11 Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses c

12 inflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction.

13 malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy (r

14 The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppr

15 efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with m

16 nd safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patie

17 Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerat

18 sion, which correlates with dampened AKT and Janus Kinase 1 signaling.

19 Expression of the activated form of Janus kinase 1 supported a role for IL-10 in prosurvival

20 validation of one of these candidates, Jak1 (Janus kinase 1), a tyrosine kinase of the nonreceptor ty

21 Finally, we determined that inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3

22 TYK2-dependent IL-12 and IL-23 signaling and Janus kinase 1-dependent signaling in cells expressing t

23 ase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) de

24 The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the

25 Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evol

26 agues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murin

27 a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.

28 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitini

29 ) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and Activator of Tr

30 n of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in v

31 Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresp

32 was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitinib.

33 e shown to be mediated through activation of Janus kinase 1/3 and GATA-3.

34 The Janus kinase 1/3 inhibitor R507 is a very well-tolerated

35 The efficacy of selective Janus kinase 1/3 inhibitor R507 to prevent obliterative

36 lso evaluated the efficacy of tofacitinib (a Janus kinase 1/3 inhibitor) in 5 patients with severe, l

37 treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repi

38 notypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to whic

39 , up-regulates heparanase expression via the Janus kinase 2 (JAK-2) pathway.

40 uired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involv

41 etic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproli

42 prevented the decrease of phosphorylation of Janus kinase 2 (JAK2) and phosphorylation of signal tran

43 nhibits interferon-gamma (IFN-gamma)-induced Janus kinase 2 (JAK2) and signal transducer and activati

44 sulting in a loss of downstream signaling by Janus kinase 2 (JAK2) and signal transducer and activato

45 ndocytic AMR controls TPO expression through Janus kinase 2 (JAK2) and the acute phase response signa

46 dermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to tran

47 Here, we investigated the role of Janus kinase 2 (JAK2) as a newly described intracellular

48 imerization and revealed that the associated Janus kinase 2 (JAK2) dimerizes through its pseudokinase

49 s in the bone marrow due to mutations in the Janus kinase 2 (JAK2) gene.

50 The nonreceptor kinase Janus kinase 2 (JAK2) has garnered attention as a promis

51 ortant axis in memory CD8(+) T cells couples Janus kinase 2 (JAK2) hyperactivation to the phosphoryla

52 s) is the acquisition of a V617F mutation in Janus kinase 2 (JAK2) in hematopoietic stem cells (HSCs)

53 ine kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.

54 ncreatic tumors were given gemcitabine and a Janus kinase 2 (JAK2) inhibitor; tumor growth was monito

55 Janus kinase 2 (JAK2) is a central kinase in hematopoiet

56 The V617F mutation in the JH2 domain of Janus kinase 2 (JAK2) is an oncogenic driver in several

57 "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2

58 Janus kinase 2 (JAK2) mutations define polycythemia vera

59 eedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer

60 Expression of Janus kinase 2 (JAK2) R867Q and S755R/R938Q induced spon

61 is controlled by cytokine receptor-mediated Janus kinase 2 (JAK2) signaling.

62 on of the phosphoinositol 3-kinase (PI3K) or Janus kinase 2 (Jak2) tyrosine kinase inhibitors abolish

63 The Janus kinase 2 (JAK2) V617F mutation is the primary path

64 combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, re

65 anism that is dependent upon beta1 integrin, Janus kinase 2 (JAK2), and STAT3 but not EGFR.

66 Phosphorylated STAT3, phosphorylated Janus kinase 2 (JAK2), and suppressor of cytokine signal

67 and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myelopro

68 receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the w

69 Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosin

70 tracytoplasmic tyrosine kinases, essentially janus kinase 2 (JAK2), which regulates MPL stability and

71 culin (CALR) mutations have been reported in Janus kinase 2 (JAK2)- and myeloproliferative leukemia (

72 red the human PRL-prolactin receptor (hPRLR)-Janus kinase 2 (JAK2)-signal transducer and activator of

73 we demonstrated that inhibition of the IL-6-Janus kinase 2 (JAK2)-STAT3-calprotectin axis with FDA-a

74 uences of Stat1 deficiency on the effects of Janus kinase 2 (JAK2)-V617F in vivo by crossing mice exp

75 sential thrombocythemia (ET) with nonmutated Janus kinase 2 (JAK2).

76 cathepsin K(+) OCs expressing phosphorylated Janus kinase 2 (JAK2).

77 Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-beta1 signaling by s

78 The inclusion of a transgenic allele of Janus kinase 2 (JAK2)V617F resulted in acceleration of t

79 patients have a gain of function mutation in Janus kinase 2 (JAK2V617F), but little is known how JAK2

80 r (MPL) to induce constitutive activation of Janus kinase 2 and signal transducer and activator of tr

81 Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferat

82 rimary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% h

83 Inhibition of Janus kinase 2 or SRC kinase signaling downstream of mut

84 In addition, the rate of Janus kinase 2 phosphorylation, initiated through the th

85 x O1, extracellular signal-regulated kinase, Janus kinase 2, or signal transducers and activators of

86 a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling i

87 tes the formation of a complex with IRS2 and Janus kinase 2, preventing IRS2 ubiquitination.

88 d PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of tran

89 s could be reversed by administration of the Janus kinase 2/3 inhibitor tofacitinib, which blocks IL-

90 cyclin-dependent kinase inhibitor), AT9283, (Janus kinase 2/3 inhibitor), ispinesib (kinesin spindle

91 d this required intact signaling through the Janus Kinase 2/phosphatidylinositol-4,5-bisphosphate 3-k

92 oid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transc

93 The critical role of Janus kinase-2 (JAK2) in regulation of myelopoiesis was

94 Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of pati

95 zed the response of bone to GH by increasing Janus kinase-2 and IGF-1R protein levels.

96 tokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transc

97 Mutations in Janus kinase 3 (JAK3) are a cause of severe combined imm

98 SGs was prevented through the activation of Janus kinase 3 (JAK3) by the vitamin K3 analog menadione

99 yromonas gingivalis enhances the activity of Janus kinase 3 (JAK3) in innate immune cells, and subseq

100 NK cells on SIV infection, use was made of a Janus kinase 3 (JAK3) inhibitor that has previously been

101 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e

102 Although constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the me

103 ling pathway mutations, including activating Janus kinase 3 (JAK3) mutations, were detected.

104 microarray-based analyses and showed reduced Janus kinase 3 (JAK3) phosphorylation upon activation.

105 mitogen-activated protein kinase (MAPK), and Janus kinase 3 (JAK3) signaling are necessary for F. tul

106 The Janus kinase 3 (JAK3) tyrosine kinase is mutated in 10%

107 r of cell lines, and the results showed that Janus kinase 3 (JAK3) was with reduced expression in the

108 phospholipase D2 (PLD2) is under control of Janus kinase 3 (JAK3), which mediates chemotaxis.

109 receptor common gamma chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T c

110 ctions during obesity are because of loss of Janus kinase 3 (JAK3)-mediated tyrosine phosphorylation

111 ), DNA-dependent protein kinase (prkdc), and janus kinase 3 (jak3).

112 ations are usually absent in the SCID-X1 and Janus kinase 3 forms of SCID and greatly reduced in aden

113 vide adequate immunosuppression, whereas the Janus kinase 3 inhibitor tofacitinib's success in the tr

114 We reported previously that Janus kinase 3, a non-receptor tyrosine kinase, plays a

115 els trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling.

116 et al. (2015) uncover multifaceted roles for janus kinase and microtubule-interacting protein 1 (JAKM

117 We originally identified Janus kinase and microtubule-interacting protein 1 (JAKM

118 by pathological activation of the JAK/STAT (Janus kinase and signal transducer and activator of tran

119 gnal from the hub cells, which activates the Janus Kinase and Signal Transducer and Activator of Tran

120 Chronic activation of Janus kinase and signal transducer and activator of tran

121 The JAnus Kinase and Signal Transducers and Activators of Tr

122 p38 mitogen-activated protein kinase (p38), Janus kinases and IL-6 have also shown some promising ef

123 eously secrete IL-17F and that inhibitors of Janus kinases and Signal transducer and activator of tra

124 Small-molecule inhibitors of the Janus kinase family (JAKis) are clinically efficacious i

125 s downstream of gp130 involved the classical Janus kinase family-signal transducer and activator of t

126 Activation of the Janus kinase family/signal transducer and activator of t

127 Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of

128 ntrate in the regulatory pseudokinase domain Janus kinase homology (JH) 2.

129 We identified a novel Janus kinase homology 2 (JH2) alphaC mutation, A598F, wh

130 ort a model of nonhierarchical activation of Janus kinases in which one catalytically competent Jak i

131 ate antiviral receptor) and TYK2 (encoding a Janus kinase), in each case establishing a further serie

132 or TNF or targeting cytokine signalling via Janus kinase inhibition in the treatment of COVID-19.

133 Other promising drugs focus on blockade of Janus kinase, inhibition of various chemokines, and biol

134 This leptin action was reduced by Janus kinase inhibitor (AG490) or PI3-kinase inhibitor (

135 an efficient and practical synthesis of the Janus kinase inhibitor (R)-tofacitinib.

136 Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.

137 Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid a

138 Although the Janus kinase inhibitor ruxolitinib provides symptomatic

139 cription 3 dependent and was impaired by the Janus kinase inhibitor ruxolitinib.

140 Tofacitinib is an oral Janus kinase inhibitor that is under investigation for t

141 Tofacitinib, an oral Janus kinase inhibitor that targets Jak1/Jak3 dependent

142 Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.

143 Janus kinase inhibitor therapy could represent an effect

144 Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis.

145 Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent ef

146 Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treat

147 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential effi

148 activity of IFN-gamma and oncostatin M, and Janus kinase inhibitors appear to be an effective treatm

149 The introduction of Janus kinase inhibitors for myelofibrosis have ushered i

150 of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option.

151 e results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatmen

152 an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in

153 cted at IL-6, the IL-6 receptor (IL-6R), and Janus kinase inhibitors.

154 Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have

155 tivation of STAT3 by inhibiting the upstream Janus kinase (JAK) 1 or JAK2 or by STAT3 knockdown was f

156 t, mediated by PKR-like ER kinase (PERK) and Janus kinase (JAK) 1.

157 Janus kinase (JAK) 1/JAK2 inhibitors are in development

158 Janus kinase (JAK) 2 plays pivotal roles in signaling by

159 Activating Janus kinase (JAK) and signal transducer and activator o

160 y administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, down

161 tential of IL-7 as a clinical target using a Janus kinase (JAK) inhibitor and an IL-7-blocking antibo

162 The Janus kinase (JAK) inhibitor ruxolitinib is the only app

163 berrant viral RNAs could be prevented by the Janus kinase (JAK) inhibitor ruxolitinib.

164 cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1.

165 Intriguingly, treatment of T cells with the Janus kinase (JAK) inhibitor tofacitinib disproportionat

166 from patients with myelofibrosis (MF) to the Janus kinase (JAK) inhibitor, AZD1480.

167 oplasms (MPN) led to clinical development of Janus kinase (JAK) inhibitors for treatment of MPN.

168 ies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart

169 More recently, clinical trials with Janus kinase (JAK) inhibitors have shown that cytokine r

170 iption 1 (STAT1), so we tested the effect of Janus kinase (JAK) inhibitors on STAT1 phosphorylation i

171 hod for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond t

172 To identify Janus kinase (JAK) inhibitors that selectively target ga

173 neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or

174 a-derived conditions enhanced sensitivity to Janus kinase (JAK) inhibitors.

175 The Janus kinase (JAK) pathway is an essential, highly re-ut

176 We show that Janus kinase (JAK) protein tyrosine kinases control chem

177 ransport, holo-RBP can activate STRA6-driven Janus kinase (JAK) signaling and downstream induction of

178 ells mediate alopecia areata in part through Janus kinase (JAK) signaling and that alopecia areata mi

179 rylation in AML leukemic blasts, the role of Janus kinase (JAK) signaling in primary AML compared wit

180 In organoids, inhibitors of Janus kinase (JAK) signaling via STAT1 (glucocorticoids,

181 The Janus kinase (JAK) system is involved in numerous cell s

182 t clones with constitutive activation of the Janus kinase (JAK)- signal transducer and activator of t

183 The Janus kinase (JAK)-inhibitor ruxolitinib decreases const

184 The Janus kinase (JAK)-signal transducer and activator of tr

185 d PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of tr

186 c cytokines via inhibition of the downstream Janus kinase (JAK)-signal transducer and activator of tr

187 F-kappaB) to the nucleus, signalling via the Janus kinase (JAK)-signal transducer and activator of tr

188 Dysregulation of Janus kinase (JAK)-signal transducer and activator of tr

189 ass I cytokine receptor that signals via the Janus kinase (JAK)-signal transducer and activator of tr

190 SGs) occurs upon activation of the canonical Janus kinase (JAK)-signal transducer and activator of tr

191 The Janus kinase (JAK)-signal transducer of activators of tr

192 clear factor-kappaB signaling pathway or the Janus kinase (JAK)-signal transducers and activators of

193 Mutations resulting in constitutive Janus kinase (JAK)-STAT activation have been detected an

194 n of adult retinal ganglion cells (RGCs) via Janus kinase (JAK)-STAT3 signalling.

195 Frequent mutations in cytokine receptor and Janus kinase (JAK)/signal transducer and activator of tr

196 Activation of the Janus kinase (JAK)/signal transducer and activator of tr

197 Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of tr

198 Because in various cells activation of the Janus kinase (JAK)/signal transducer and activator of tr

199 ent study was to investigate the role of the Janus kinase (JAK)/signal transducer and activator of tr

200 diabetes complications, such as elements of Janus kinase (JAK)/signal transducer and activator of tr

201 egulation of Jun N-terminal Kinase (JNK) and Janus Kinase (JAK)/Signal Transducer and Activator of Tr

202 mor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of tr

203 Chronic activation of the Janus kinase (JAK)/signal transducer and activator of tr

204 leukaemia-initiation potential and activated Janus kinase (JAK)/signal transducers and activators of

205 e) inducing a constitutive activation of the Janus kinase (JAK)/STAT pathway.

206 n the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to

207 Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy

208 Ruxolitinib is an FDA approved janus kinase (JAK)1/2 inhibitor used to treat myeloproli

209 mutation leads to constitutive activation of Janus kinase (JAK)2 and contributes to dysregulated JAK

210 The discovery of the Janus kinase (JAK)2 mutation triggered the development o

211 The Janus kinase (JAK)2/signal transducer and activator of t

212 or hetero-dimeric cell surface receptors via Janus Kinase (JAK/TYK), or Receptor Tyrosine Kinase (RTK

213 results in activation of receptor-associated Janus kinases (Jak) and phosphorylation of STAT proteins

214 Janus kinases (Jak) play essential roles in cytokine and

215 Recent studies have shown that Janus kinases (JAK), JAK1, and JAK2, play an important r

216 uch cases harboring somatic mutations in the Janus kinases JAK1 and JAK2.

217 In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential

218 Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved

219 ansduces a signaling cascade mediated by the Janus kinase JAK2 and the transcription factors STAT3 an

220 For this, they differentially use the Janus kinase (Jak2) and phosphatidylinositol 3-kinase (P

221 ese cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activato

222 We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3

223 The Janus kinases (JAKs) and their downstream effectors, sig

224 The Janus kinases (JAKs) are a family of intracellular tyros

225 Inhibitors of Janus kinases (JAKs) are being developed for treatment o

226 Janus kinases (JAKs) are non-receptor tyrosine kinases t

227 Janus kinases (JAKs) are nonreceptor tyrosine kinases wi

228 Janus kinases (JAKs) are receptor-associated multidomain

229 Janus kinases (JAKs) are regulators of signaling through

230 Activated Janus kinases (JAKs) are required for T-effector cell re

231 Janus kinases (JAKs) classically signal by activating ST

232 The data revealed that Janus kinases (JAKs) couple IL-2 receptors to the coordi

233 TATs), essential functions of their upstream Janus kinases (JAKs) during postnatal development are le

234 Janus kinases (JAKs) have a key role in regulating the e

235 The action of Janus kinases (JAKs) is required for multiple cytokine s

236 Janus kinases (JAKs) mediate responses to cytokines, hor

237 The Janus kinases (JAKs) transduce signals initiated followi

238 ated kinases (ERKs), protein kinase B (Akt), Janus kinases (JAKs), and signal transducer activator of

239 signaling molecules, including ERK, Akt, and Janus kinases (Jaks), especially those that mediate infl

240 Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2)

241 orylated potentially on the basis of reduced Janus kinase-mediated inhibition of protein phosphatase

242 hocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibito

243 adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adhesion-associated proteins,

244 ic FXR hyperacetylation and induction of the Janus kinase/p53 pathway.

245 Signaling from JAK (Janus kinase) protein kinases to STAT (signal transducer

246 b and ruxolitinib, which inhibit BCR-ABL and Janus kinases, respectively), significantly extends surv

247 N including utilization of the intracellular Janus kinase signal transducer and activator of transcri

248 Socs36E encodes an inhibitor of the Janus kinase signal transducer and activator of transcri

249 cells whose development is dependent on the Janus kinase-signal transducer and activator of transcri

250 cation after blocking the interferon-induced Janus kinase-signal transducer and activator of transcri

251 as the phosphoinositide 3-kinase (PI3K) and Janus kinase-signal transducer and activator of transcri

252 n ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcri

253 a higher frequency of mutations outside the Janus kinase-signal transducer and activator of transcri

254 Mechanistically, loss of SH2B3 increases Janus kinase-signal transducer and activator of transcri

255 2V617F exerts its effects on cell growth via janus kinase-signal transducer and activator of transcri

256 The Janus kinase-signal transducer and activator of transcri

257 Defective regulation of the Janus kinase-signal transducer and activator of transcri

258 highly recurrent oncogenic mutations in the Janus kinase-signal transducer and activator of transcri

259 erization domain-like receptor signaling and Janus kinase-signal transducer and activator of transcri

260 n Drosophila by the evolutionarily conserved Janus kinase-signal transducers and activators of transc

261 d BALF ILs and cytokines including Jak-STAT (Janus kinases-signal transducer and activator of transcr

262 It is known that Janus kinase/signal transducer and activator of transcri

263 origenic overgrowth by exploiting endogenous Janus kinase/signal transducer and activator of transcri

264 Combined, these data show that an IL-10/Janus kinase/signal transducer and activator of transcri

265 induce Bim in normal and ALPS T cells via a Janus kinase/signal transducer and activator of transcri

266 The Janus kinase/signal transducer and activator of transcri

267 , ruxolitinib, an inhibitor of IFN-triggered Janus kinase/signal transducer and activator of transcri

268 ays, such as TCRs, nuclear factor kappaB, or Janus kinase/signal transducer and activator of transcri

269 ingless-related integration site), JAK-STAT (Janus kinase/signal transducer and activator of transcri

270 cell-like diffuse cell lymphoma and enhanced Janus kinase/signal transducer and activator of transcri

271 e signature in CLL, containing components of Janus kinase/signal transducer and activator of transcri

272 tiviral response by activating the JAK/STAT (Janus kinase/signal transducer and activator of transcri

273 flammatory gene sets such as IL-6/JAK/STAT5 (Janus kinase/signal transducer and activator of transcri

274 Conserved from humans to Drosophila, the Janus kinase/signal transducer and activators of transcr

275 Mechanistically, IRS-1 deficiency promotes Janus kinase/signal transducers and activators of transc

276 Here, we emphasize Janus kinase/signal transducers and activators of transc

277 Accumulating evidence points to a role for Janus kinase/signal transducers and activators of transc

278 erleukin-6 (IL-6) secretion, which activates Janus kinase/signal transducers and activators of transc

279 Secreted IFNs activate the Janus kinase/signal transducers and activators of transc

280 e that IL-4 up-regulates pIgR production via Janus kinase/signal transducers and activators of transc

281 The Janus kinase/Signal transducers and activators of transc

282 The Janus-kinase/signal transducer and activator of transcri

283 Inhibition of Janus kinase signaling during controlled mechanical vent

284 ts of IL22 were prevented with inhibitors of Janus kinase signaling to signal transducer and activato

285 ndent of IFNalpha, IFNbeta, IFNL1, IFNL2, or Janus kinase signaling via signal transducer and activat

286 d with CMV can be prevented by inhibition of Janus kinase signaling.

287 The Janus kinase/spleen tyrosine kinase inhibitor ASN002 sig

288 ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways,

289 late kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyr

290 The MEK inhibitor trametinib, the Janus kinase-STAT inhibitor tofacitinib, and the STAT5 i

291 am transcriptional program and activates the Janus kinase-STAT signaling cascade and thus, by interfe

292 with the IL28B-T/T variant preactivates the Janus kinase-Stat signaling, leading to impaired HCV cle

293 iasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte

294 y indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells.

295 rget three major cellular processes: (i) the Janus kinase/STAT5 pathway (ii) progenitor B-cell differ

296 y, binding of agonist to receptors activates Janus kinases that phosphorylate cytoplasmic STAT3 at ty

297 Genetic studies have linked the Janus kinase TYK2 to AS.

298 The Janus kinase tyrosine kinase (Tyk) 2 associates with IL-

299 and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in bloc

300 lated protein kinases, protein kinase B, and Janus kinase, which are activated by chemotherapeutics i